Jan 9 (Reuters) – Celgene Corp on Monday raised its
2017 revenue and profit forecasts on the strength of its
flagship Revlimid multiple myeloma drug and increased
expectations for other treatments…
The post UPDATE 2-Celgene raises 2017 revenue, profit forecast; maintains 2020 view appeared first on NASDAQ.